
First published in the *Government Gazette*, Electronic Edition, on 23 July 2024 at 5 pm.

No. S 607

**MEDICAL AND ELDERLY CARE
ENDOWMENT SCHEMES ACT 2000**

**MEDICAL AND ELDERLY CARE ENDOWMENT SCHEMES
(MEDIFUND COMMITTEES) (AMENDMENT NO. 5)
ORDER 2024**

In exercise of the powers conferred by section 14 of the Medical and Elderly Care Endowment Schemes Act 2000, the Minister for Health makes the following Order:

Citation and commencement

1. This Order is the Medical and Elderly Care Endowment Schemes (Medifund Committees) (Amendment No. 5) Order 2024 and comes into operation on 1 August 2024.

Amendment of paragraph 2

2. In the Medical and Elderly Care Endowment Schemes (Medifund Committees) Order 2015 (G.N. No. S 361/2015) (called in this Order the principal Order), in paragraph 2 —

- (a) in sub-paragraph (1), replace “Parts 1 and 2” with “Parts 1, 2 and 3”;
- (b) in sub-paragraph (2)(a), after “all classes of eligible patients”, insert “(other than the class of eligible patients mentioned in sub-paragraph (4)(a))”; and
- (c) after sub-paragraph (3), insert —

“(4) A Medifund committee named in the first column of Part 3 of the Schedule may —

- (a) consider and approve applications under section 15 of the Act from an eligible patient who has received treatment or requires treatment involving the

administration of any cell, tissue or gene therapy product from one or more approved institutions designated in the second column of Part 3 of the Schedule corresponding to the Medifund committee; and

- (b) exercise the powers and perform the duties under Part 2 of the Act in relation to those approved institutions and the eligible patient.

(5) For the purposes of sub-paragraph (4), the hospital charges, fees and other expenses forming the subject matter of an application include any hospital charges, fees and other expenses incurred by the eligible patient for any other treatment received by him or her from the approved institution which does not involve the administration of any cell, tissue or gene therapy product if, and only if, such other treatment is received within the same hospitalisation period as the treatment involving the administration of any cell, tissue or gene therapy product from the approved institution.

- (6) In this paragraph —

“cell, tissue or gene therapy product” has the meaning given by the First Schedule to the Health Products Act 2007;

“hospitalisation period” means the period starting on the day an eligible patient is admitted to an approved institution and ending on (and including) the day the eligible patient is discharged from the approved institution.”.

Amendment of Schedule

3. In the principal Order, in the Schedule, after Part 2, insert —
- “PART 3

<i>First column</i>	<i>Second column</i>
Name of Medifund committee	Approved institutions
1. Central Medifund Committee	(1) Admiralty Medical Centre (2) Changi General Hospital (3) Jurong Community Hospital (4) Jurong Medical Centre (5) Khoo Teck Puat Hospital (6) KK Women’s and Children’s Hospital (7) National Cancer Centre (8) National Dental Centre (9) National Healthcare Group Polyclinics (10) National Heart Centre (11) National Neuroscience Institute (12) National Skin Centre (13) National University Hospital (14) National University Polyclinics (15) Ng Teng Fong General Hospital (16) Outram Community Hospital (17) Sengkang Community Hospital (18) Sengkang General Hospital (19) Singapore General Hospital (20) Singapore National Eye Centre

	(21) SingHealth Polyclinics
	(22) Tan Tock Seng Hospital
	(23) Woodbridge Hospital/Institute of Mental Health
	(24) WoodlandsHealth Pte. Ltd.
	(25) Yishun Community Hospital „

Saving and transitional provision

4. Paragraph 2(2) of the principal Order as in force immediately before 1 August 2024 continues to apply in relation to any application made under section 15 of the Act before that date by an eligible patient mentioned in paragraph 2(4)(a) of the principal Order as in force on that date of any approved institution designated in the second column of Part 3 of the Schedule to the principal Order as in force on that date.

[G.N. Nos. S 377/2015; S 462/2015; S 548/2015; S 569/2015; S 579/2015; S 603/2015; S 784/2015; S 805/2015; S 10/2016; S 72/2016; S 95/2016; S 291/2016; S 434/2016; S 486/2016; S 528/2016; S 19/2017; S 145/2017; S 157/2017; S 255/2017; S 328/2017; S 376/2017; S 428/2017; S 437/2017; S 519/2017; S 584/2017; S 642/2017; S 43/2018; S 149/2018; S 226/2018; S 395/2018; S 421/2018; S 473/2018; S 525/2018; S 759/2018; S 9/2019; S 36/2019; S 84/2019; S 318/2019; S 494/2019; S 758/2019; S 97/2020; S 153/2020; S 337/2020; S 470/2020; S 978/2020; S 79/2021; S 165/2021; S 300/2021; S 498/2021; S 611/2021; S 658/2021; S 794/2021; S 51/2022; S 172/2022; S 307/2022; S 376/2022; S 818/2022; S 72/2023; S 285/2023; S 575/2023; S 646/2023; S 684/2023; S 828/2023; S 97/2024; S 418/2024; S 466/2024; S 518/2024]

Made on 19 July 2024.

LAI WEI LIN
Permanent Secretary
(Policy and Development),
Ministry of Health,
Singapore.

[MH 40:11/77-38; AG/LEGIS/SL/173A/2020/1]